Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases (RADAR)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2012 by German Breast Group.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT00466102
First received: April 25, 2007
Last updated: August 29, 2012
Last verified: August 2012
  Purpose

The purpose of this study is to determine wether RAD001 can inhibit growth of tumour cells and/or stop the formation and activity of bone degrading osteoclasts.


Condition Intervention Phase
Breast Cancer
Drug: RAD001
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: RADAR: A Randomized Discontinuation Phase II Study to Determine the Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

Resource links provided by NLM:


Further study details as provided by German Breast Group:

Primary Outcome Measures:
  • To determine the time to progression (TTP) in patients with no change in bone metastases after an 8 week run in treatment with RAD001 compared to placebo [ Time Frame: 40 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine the objective response rate after 8 weeks of RAD001 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • To determine the TTP in patients with a response after 8 weeks of RAD001 [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • To determine the overall clinical benefit defined as CR, PR or stable disease > 24 weeks for patients continuing RAD001 after the 8 week run in phase [ Time Frame: 40 weeks ] [ Designated as safety issue: No ]
  • To evaluate the safety and toxicity of RAD001 [ Time Frame: 40 weeks ] [ Designated as safety issue: Yes ]
  • To assess the frequency of bone related events [ Time Frame: 40 weeks ] [ Designated as safety issue: Yes ]
  • To assess changes of pain intensity during treatment [ Time Frame: 40 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 130
Study Start Date: December 2006
Estimated Study Completion Date: December 2012
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Patients with stable disease after 8 week run in randomized to RAD001 (blinded)
Drug: RAD001
Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
Placebo Comparator: 2
Patients with stable disease after 8 week run in receive placebo (blinded)
Drug: Placebo
2 tablets are taken once daily during study therapy

Detailed Description:

RAD001 is an orally bioavailable and well tolerated rapamycin ester analogue, which acts by selectively inhibiting mTOR (mammalian target of rapamycin). mTor is an intracellular protein kinase implicated in the control of cellular proliferation in neoplastic cells. Treatment with RAD001 has been shown to inhibit these signalling events and leads to growth retardation of tumour cells. In addition RAD001 in vitro stops the formation and activity of osteoclasts. Therefore a therapy of advanced breast cancer with progressive bone metastases seems to be reasonable with RAD001.

Comparison:

All patients receive RAD001 in an 8 week run in phase. Patients who show a response after 8 weeks will continue receiving RAD001. All patients with stable disease after the run in phase will be randomised to receive either RAD001 or placebo and will be followed up until progression of disease. Patients with progressive disease after the 8 week run in phase will be withdrawn from the trial.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements.
  • Histologically confirmed invasive adenocarcinoma of the breast.
  • Primary tumour or metastasis negative or positive (≥ 10% positive stained cells) for oestrogen and/or progesterone receptor detected by immunohistochemistry.
  • Single or multiple bone metastasis (x-ray, CT or MRI) as only metastatic site.
  • Postmenopausal hormone receptor positive patients should have received an aromatase inhibitor in any given previous breast cancer therapy. Concurrent endocrine treatment for metastatic bone disease is obligatory. Previous treatment with bisphosphonates is allowed.
  • Up to one previous chemotherapy for metastatic disease is allowed.
  • Patients must have either measurable or non-measurable target lesions according to the WHO criteria.
  • At least 1 target lesion must be completely outside the radiation portal or there must be pathologic proof of progressive disease.
  • At least 2 weeks since major surgery with full recovery.
  • Complete staging within 4 weeks prior to registration.
  • Karnofsky performance status evaluation > 60%.
  • Age >18 years.
  • Absolute neutrophil count >1,500 cells/µl, platelet count >100,000 cells/µl.
  • Bilirubin >1.5x the upper normal limit for the institution (UNL); elevation of transaminases, alkaline phosphatase < 2.5x UNL and serum albumin < 30g/l. Normal renal function (creatinine >1.5x upper normal limit)
  • If of childbearing potential, negative pregnancy test. In addition the patient has to agree to use an effective method to avoid pregnancy for the duration of the study.

Exclusion Criteria:

  • Known hypersensitivity reaction to the compounds or incorporated substances (e.g. everolimus or sirolimus [rapamycin] or lactose).
  • Concurrent immunotherapy or hormone replacement therapy and use of hormonal contraceptives.
  • Need for chemotherapy or irradiation of bone metastasis during study treatment
  • HER2 positive primary tumour and/or lesion
  • Evidence of metastasis in other organs
  • Uncompensated diabetes mellitus; fasting value of blood sugar of >120 (mg/dl)
  • Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00 mmol/l) or > 12.0 mg/dl (3.00 mmol/l)
  • Abnormal renal function as evidenced by a calculated creatinine clearance < 30 ml/minute
  • Life expectancy of less than 3 months
  • Serious intercurrent medical or psychiatric illness that may interfere with the planned treatment (including AIDS and serious active infection).
  • History of other malignancy within the last 5 years which could affect the diagnosis or assessment of metastatic breast cancer
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
  • Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (e.g. rifabutin, rifampicin, clarithromycin, ketoconazole, itraconazole, ritonavir, telithromycin, erythromycin, verapamil, dilitazem) within the last 5 days or the expected need for these treatments during study participation.
  • Pregnant or nursing women.
  • The patient is not accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre which could be the Principal or Co-Investigator's site.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00466102

Locations
Germany
Dr. med. Christoph Mundhenke
Kiel, Schleswig-Holstein, Germany, 24105
Sponsors and Collaborators
German Breast Group
Novartis
Investigators
Principal Investigator: Nicolai Maass, MD, Prof. Universitätsfrauenklinik Aachen
  More Information

Additional Information:
No publications provided

Responsible Party: German Breast Group
ClinicalTrials.gov Identifier: NCT00466102     History of Changes
Other Study ID Numbers: GBG 41
Study First Received: April 25, 2007
Last Updated: August 29, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by German Breast Group:
Breast Cancer
Bone metastases as only metastatic site
Breast cancer, HER2 negative
Bone metastasis as only metastatic site
Pretreated with endocrine therapy
Up to one previous chemotherapy
Previous treatment with bisphosphonates allowed

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasm Metastasis
Breast Diseases
Neoplasms
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Skin Diseases
Everolimus
Sirolimus
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014